PriceTargets.com logo

NeuroPace - NPCE Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $14.50
  • Forecasted Upside: 25.76%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$11.53 As of 12/20/2024 06:16 PM ET
▲ +0.39 (3.50%)

This chart shows the closing price for NPCE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeuroPace Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NPCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NPCE

Analyst Price Target is $14.50
▲ +25.76% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for NeuroPace in the last 3 months. The average price target is $14.50, with a high forecast of $22.00 and a low forecast of $8.00. The average price target represents a 25.76% upside from the last price of $11.53.

This chart shows the closing price for NPCE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 contributing investment analysts is to moderate buy stock in NeuroPace. This rating has held steady since October 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/17/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$9.00 ➝ $14.00
11/13/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$15.00 ➝ $13.00
8/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$18.00 ➝ $18.00
8/14/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$20.00 ➝ $15.00
7/15/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$9.50 ➝ $8.00
5/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$18.00
3/14/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$16.00 ➝ $20.00
3/6/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$9.00 ➝ $13.00
3/6/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$16.00 ➝ $18.00
2/22/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$9.00 ➝ $16.00
1/30/2024Leerink PartnrsReiterated RatingOutperform
1/30/2024Leerink PartnersInitiated CoverageOutperform$22.00
12/27/2023Lake Street CapitalReiterated RatingBuy ➝ Buy$12.00
12/4/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$8.00 ➝ $9.00
11/14/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$6.00 ➝ $8.00
11/10/2023Cantor FitzgeraldInitiated CoverageOverweight$11.00
11/7/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$6.00 ➝ $9.00
10/4/2023Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$6.00 ➝ $9.00
8/24/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight$5.00 ➝ $6.00
3/3/2023Morgan StanleyBoost TargetUnderweight$2.50 ➝ $4.50
2/22/2023Lake Street CapitalInitiated CoverageBuy$10.00
1/6/2023Morgan StanleyLower TargetUnderweight$3.50 ➝ $2.50
10/11/2022Morgan StanleyLower TargetUnderweight$5.50 ➝ $3.50
7/15/2022Morgan StanleyLower TargetUnderweight$6.00 ➝ $5.50
4/5/2022Wolfe ResearchInitiated CoverageOutperform$13.00
3/11/2022Wells Fargo & CompanyLower TargetEqual Weight$11.00 ➝ $9.00
3/11/2022Leerink PartnersLower TargetOutperform$15.00 ➝ $12.00
1/19/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$11.00
1/7/2022Morgan StanleyDowngradeEqual Weight ➝ Underweight$17.00 ➝ $12.00
11/14/2021Leerink PartnersReiterated RatingBuy$30.00
11/11/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$24.00 ➝ $17.00
11/11/2021Wells Fargo & CompanyLower TargetOverweight$28.00 ➝ $20.00
8/17/2021Robert W. BairdInitiated CoverageOutperform$26.00
8/15/2021Leerink PartnersReiterated RatingBuy$30.00
6/3/2021Leerink PartnersBoost TargetOutperform$25.00 ➝ $30.00
5/17/2021Leerink PartnersInitiated CoverageOutperform$25.00
5/17/2021Wells Fargo & CompanyInitiated CoverageOverweight$25.00
5/17/2021JPMorgan Chase & Co.Initiated CoverageOverweight$27.00
5/17/2021Morgan StanleyInitiated CoverageOverweight$26.00
(Data available from 12/22/2019 forward)

News Sentiment Rating

0.50 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/25/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/24/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2024
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2024
  • 10 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2024

Current Sentiment

  • 4 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NeuroPace logo
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $11.53
Low: $10.76
High: $11.59

50 Day Range

MA: $8.81
Low: $5.90
High: $11.93

52 Week Range

Now: $11.53
Low: $5.45
High: $18.15

Volume

188,294 shs

Average Volume

95,864 shs

Market Capitalization

$344.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.05

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuroPace?

The following Wall Street analysts have issued stock ratings on NeuroPace in the last year: Cantor Fitzgerald, JPMorgan Chase & Co., Lake Street Capital, Leerink Partners, Leerink Partnrs, Morgan Stanley, and Wells Fargo & Company.
View the latest analyst ratings for NPCE.

What is the current price target for NeuroPace?

0 Wall Street analysts have set twelve-month price targets for NeuroPace in the last year. Their average twelve-month price target is $14.50, suggesting a possible upside of 25.8%. Leerink Partners has the highest price target set, predicting NPCE will reach $22.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $8.00 for NeuroPace in the next year.
View the latest price targets for NPCE.

What is the current consensus analyst rating for NeuroPace?

NeuroPace currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NPCE.

What other companies compete with NeuroPace?

Other companies that are similar to NeuroPace include Establishment Labs, BioLife Solutions, Pulse Biosciences, Artivion and Embecta. Learn More about companies similar to NeuroPace.

How do I contact NeuroPace's investor relations team?

The company's listed phone number is 650-237-2700 and its investor relations email address is [email protected]. The official website for NeuroPace is www.neuropace.com. Learn More about contacing NeuroPace investor relations.